BRNH.F Stock Overview
A medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Broncus Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.08 |
| 52 Week High | HK$0.12 |
| 52 Week Low | HK$0.08 |
| Beta | 0.89 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRNH.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | 20.8% | 31.6% |
Return vs Industry: Insufficient data to determine how BRNH.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how BRNH.F performed against the US Market.
Price Volatility
| BRNH.F volatility | |
|---|---|
| BRNH.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BRNH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BRNH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 314 | Hong Xu | www.broncus.com |
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker that is used to mark the location of the lung nodule to achieve precise positioning during surgical pneumonectomy.
Broncus Holding Corporation Fundamentals Summary
| BRNH.F fundamental statistics | |
|---|---|
| Market cap | US$45.79m |
| Earnings (TTM) | -US$26.71m |
| Revenue (TTM) | US$11.43m |
4.0x
P/S Ratio-1.7x
P/E RatioIs BRNH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRNH.F income statement (TTM) | |
|---|---|
| Revenue | US$11.43m |
| Cost of Revenue | US$2.55m |
| Gross Profit | US$8.88m |
| Other Expenses | US$35.59m |
| Earnings | -US$26.71m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 77.69% |
| Net Profit Margin | -233.68% |
| Debt/Equity Ratio | 0.01% |
How did BRNH.F perform over the long term?
See historical performance and comparison